[Clinical study on micronomicin in the field of internal medicine].
From clinical study on micronomicin (MCR) [Sagamicin, KW-1062], the following results were obtained. MCR was administered clinically at the daily dose of 120--240 mg for 1--45 days to 23 patients. The clinical effectiveness rate of MCR was 72.7% in all cases. As side effects, exanthema, drop of blood pressure and shortness of breath were observed in 1 patient (malignant lymphoma). Elevations of S-GOT, S-GPT and BUN were encountered in some patients. However, these results might not be due to the administration of MCR, because antitumor agents on the blood transfusion had been applied to the patients suffering from underlying diseases such as leukemia or malignant tumor. Side effects, such as impairment of the 8th nerve, renal and liver function were not noted. MCR is considered to be a useful antibiotic in the treatment of various infectious diseases combined with underlying diseases, such as progressive cancer and leukemia, and the infectious diseases of the aged.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D005839:Gentamicins; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; C037545:micronomicin